How do these regulations impact clinical trials involving children?
These regulations mandate that new drugs must undergo clinical trials involving children if the drug is likely to be used in pediatric populations. This ensures that medications are safe and effective for children, reducing the risk of adverse reactions. The European Medicines Agency (EMA) also has similar requirements through its Pediatric Investigation Plans (PIPs).
